Search results
EULAR 2024 Preview: What's Not to Miss?
Medscape· 4 days agoEULAR 2024 Preview: What's Not to Miss at This Year's Congress? The European Alliance of Associations for Rheumatology (EULAR) 2024 European Congress of...
Forever Young: Simple Steps to Keep Neck Pain, Muscle Aches and More Away
Closer Weekly via Yahoo News· 2 days agoFollow these simple steps for better mobility and strength. Stretch It Out Per the experts at...
A Pa. teen is navigating a rare genetic condition. Her family says insurance calls the shots
WHYY· 3 days agoFrom Philly and the Pa. suburbs to South Jersey and Delaware, what would you like WHYY News to...
Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and...
KOLR - KSFX Ozarks· 12 hours agoProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by ...
Walmart Is Selling a 'Beautiful' Boho Dresser That Looks Just Like a Crate & Barrel Version That's...
Parade· 2 days agoEach drawer has a rattan panel on the front that gives it a tropical vibe that perfectly fits in...
New drug in Duke-led clinical trial shows improvement in people with common autoimmune disease
WUNC Chapel Hill· 6 days agoA new drug has shown benefits in clinical trials for one of the most common autoimmune diseases. Sjögren’s disease affects an estimated 1 to 4 million people in the United States. “About a quarter ...
More Tender Than Swollen Joints Worsen Outcomes in Early RA
Medscape· 7 days agoPatients with early rheumatoid arthritis who had higher tender-swollen joint differences showed...
AbbVie's tight grip on Humira market raises concerns about biosimilars
Reuters via Yahoo News· 7 days agoAbbVie’s top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine...
AbbVie's tight grip on Humira market raises concerns about biosimilars
AOL· 7 days agoHumira, which lists for almost $7,000 a month, is the first top-selling drug to compete with a slew of biosimilars, which are close but not exact copies of branded biologic medicines. But after ...